<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00289536</url>
  </required_header>
  <id_info>
    <org_study_id>060403</org_study_id>
    <nct_id>NCT00289536</nct_id>
  </id_info>
  <brief_title>Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A</brief_title>
  <official_title>Advate Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (ADVATE rAHF-PFM): A Phase 4 Study to Determine the Pharmacokinetic Response of Patients Diagnosed With Severe Hemophilia A to Different Doses of ADVATE rAHF-PFM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of 3 doses of ADVATE rAHF-PFM on initial
      recovery (% increase [IU/dL] per IU/kg infused) and major single-infusion pharmacokinetic
      parameters. The 3 doses are 15, 30, and 50 IU/kg. Prior to each infusion, subjects will not
      have received treatment with a factor VIII concentrate for at least 3 days. Blood samples
      will be drawn within 30 minutes pre-infusion and at 0.25, 0.5, 1, 3, 6, 9, 24, 28, 32 and 48
      hours post-infusion. A washout period of at least 3 days, but no more than 30 days between
      the last blood draw and the next infusion will be observed. During participation, subjects
      will maintain their preexisting treatment regimens with ADVATE rAHF-PFM or other factor VIII
      concentrate.

      A secondary objective is to investigate the relationship between pharmacokinetic parameters
      at each dose level and the levels of von Willebrand factor ristocetin cofactor activity and
      von Willebrand factor antigen at baseline.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initial Recovery</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion to 30 minutes post-infusion</time_frame>
    <description>Percent increase in factor VIII concentration per dose from pre- to post-infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve/Dose</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Area under the plasma factor VIII concentration versus time curve (AUC) estimated by linear trapezoidal method per dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Computed from the regression slope in the terminal phase of the model (the slope is biphasic). Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Area Under the Curve</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Total AUC with extrapolation using the slope of the β-phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Area Under the Moment Curve</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Total area under the first moment curve (AUMC) estimated by linear trapezoidal methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-adjusted Clearance</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Computed as weight-adjusted dose divided by total AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Computed as total AUMC divided by total AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Computed as weight-adjusted CL * Mean Residence Time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Maximal factor VIII concentration after infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-infusion Von Willebrand Factor Ristocetin Cofactor Activity (VWF:Rco)</measure>
    <time_frame>At baseline and before each pharmacokinetic evaluation</time_frame>
    <description>Percentage of normal VWF:Rco activity. Normal is a lab standard consisting of a non-hemophilic population. Relationships between baseline VWF:Rco and pharmacokinetic parameters (initial recovery, total AUC/dose, and half-life) were evaluated statistically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-infusion Von Willebrand Factor Antigen (VWF:Ag)</measure>
    <time_frame>At baseline and before each pharmacokinetic evaluation</time_frame>
    <description>Percentage of VWF:Ag. Relationships between baseline VWF:Ag and pharmacokinetic parameters (initial recovery, total AUC/dose, and half-life) were evaluated statistically.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Antihemophilic factor, recombinant, manufactured protein-free</intervention_name>
    <description>15 IU/kg rAHF-PFM</description>
    <arm_group_label>Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Antihemophilic factor, recombinant, manufactured protein-free</intervention_name>
    <description>30 IU/kg rAHF-PFM</description>
    <arm_group_label>Medium Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Antihemophilic factor, recombinant, manufactured protein-free</intervention_name>
    <description>50 IU/kg rAHF-PFM</description>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has severe hemophilia A as defined by a baseline factor VIII activity &lt;1%
             of normal; tested at screening. (A minimum washout period of 3 days is required before
             the blood sample can be drawn to determine baseline factor VIII levels.)

          -  The subject has a documented history of at least 150 exposure days to factor VIII
             concentrates (either plasma-derived or recombinant).

          -  The subject is within 12 to 65 years of age.

          -  The subject has a Karnofsky performance score &gt;60.

          -  The subject is human immunodeficiency virus negative (HIV-) or HIV+ with CD4 count
             &gt;=400 cells/mm3 (CD4 count determined at screening, if necessary).

          -  The subject or subject´s legally authorized representative has provided written
             informed consent.

        Exclusion Criteria:

          -  The subject has a known hypersensitivity to mouse or hamster proteins or to factor
             VIII concentrates.

          -  The subject has a history of factor VIII inhibitors with titer &gt;=0.8 BU (Bethesda
             Assay) or &gt;=0.4 BU (Nijmegen modification of the Bethesda Assay) any time prior to
             screening.

          -  The subject has a detectable factor VIII inhibitor at screening, &gt;=0.4 BU (Nijmegen
             modification of the Bethesda Assay), in the Baxter central laboratory.

          -  The subject has severe chronic liver disease as evidenced by, but not limited to, any
             of the following: International Normalized Ratio (INR) &gt;1.4, hypoalbuminemia, portal
             vein hypertension including presence of otherwise unexplained splenomegaly and history
             of esophageal varices.

          -  The subject has been diagnosed with an inherited or acquired hemostatic defect other
             than hemophilia A (e.g. qualitative platelet defect or von Willebrand´s Disease).

          -  The subject has participated in another investigational study within 30 days of
             enrollment.

          -  The subject´s clinical condition may require a major or moderate surgery (estimated
             blood loss &gt;500 mL) during the period of participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ralph Gruppo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinnati Children´s Hospital Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Tarantino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comprehensive Bleeding Disorders Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge Di Paola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire Philipp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Medicine &amp; Dentistry of NJ, Robert Wood Johnson Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kapil Saxena, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma HSC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Doris V Quon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Los Angeles Orthopaedic Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kimo Stine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arkansas Children´s Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2006</study_first_submitted>
  <study_first_submitted_qc>February 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2006</study_first_posted>
  <results_first_submitted>September 30, 2010</results_first_submitted>
  <results_first_submitted_qc>December 8, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2011</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <name_title>Jorge Escobar, Clinical Project Manager</name_title>
    <organization>Baxter Healthcare Corporation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was conducted in the United States at 8 study sites.</recruitment_details>
      <pre_assignment_details>Participants were screened for a maximum of 30 days. Participants were randomized to a single sequence of the 3 doses of Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM). Before each pharmacokinetic evaluation, at least a 3 day washout period and negative factor VIII inhibitor titer was required.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose</title>
          <description>15 IU/kg rAHF-PFM</description>
        </group>
        <group group_id="P2">
          <title>Medium Dose</title>
          <description>30 IU/kg rAHF-PFM</description>
        </group>
        <group group_id="P3">
          <title>High Dose</title>
          <description>50 IU/kg rAHF-PFM</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10">5 participants received Medium Dose and 5 participants received High Dose in Period 1</participants>
                <participants group_id="P2" count="9">5 participants received Low Dose and 4 participants received High Dose in Period 1</participants>
                <participants group_id="P3" count="7">4 participants received Low Dose and 3 participants received Medium Dose in Period 1</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7">3 participants received Medium Dose and 4 participants received High Dose in Period 2</participants>
                <participants group_id="P2" count="9">5 participants received Low Dose and 4 participants received High Dose in Period 2</participants>
                <participants group_id="P3" count="10">5 participants received Low Dose and 5 participants received Medium Dose in Period 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treated Participants</title>
          <description>Participants who received at least 1 infusion of rAHF-PFM.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.8" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Initial Recovery</title>
        <description>Percent increase in factor VIII concentration per dose from pre- to post-infusion</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion to 30 minutes post-infusion</time_frame>
        <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>15 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose</title>
            <description>30 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>50 IU/kg rAHF-PFM</description>
          </group>
        </group_list>
        <measure>
          <title>Initial Recovery</title>
          <description>Percent increase in factor VIII concentration per dose from pre- to post-infusion</description>
          <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
          <units>IU/dL per IU/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.5" upper_limit="2.7"/>
                    <measurement group_id="O2" value="1.6" lower_limit="0.4" upper_limit="2.6"/>
                    <measurement group_id="O3" value="1.8" lower_limit="1.2" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: The mean log initial recovery will be the same in each dose group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1662</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA with dose as fixed effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve/Dose</title>
        <description>Area under the plasma factor VIII concentration versus time curve (AUC) estimated by linear trapezoidal method per dose.</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>15 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose</title>
            <description>30 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>50 IU/kg rAHF-PFM</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve/Dose</title>
          <description>Area under the plasma factor VIII concentration versus time curve (AUC) estimated by linear trapezoidal method per dose.</description>
          <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
          <units>IU*hour/dL per IU/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" lower_limit="8.8" upper_limit="43.3"/>
                    <measurement group_id="O2" value="20.5" lower_limit="6.5" upper_limit="42.2"/>
                    <measurement group_id="O3" value="22.3" lower_limit="14.5" upper_limit="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: The mean log AUC/dose will be the same in each dose group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0965</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA with dose as fixed effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life</title>
        <description>Computed from the regression slope in the terminal phase of the model (the slope is biphasic). Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>15 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose</title>
            <description>30 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>50 IU/kg rAHF-PFM</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life</title>
          <description>Computed from the regression slope in the terminal phase of the model (the slope is biphasic). Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.</description>
          <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="5.4" upper_limit="19.9"/>
                    <measurement group_id="O2" value="12.3" lower_limit="6.0" upper_limit="20.0"/>
                    <measurement group_id="O3" value="11.2" lower_limit="7.5" upper_limit="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: The mean terminal half-life will be the same in each dose group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5057</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA with dose as fixed effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve</title>
        <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>15 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose</title>
            <description>30 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>50 IU/kg rAHF-PFM</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve</title>
          <description>AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.</description>
          <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
          <units>IU*hour/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300.1" lower_limit="124.5" upper_limit="544.9"/>
                    <measurement group_id="O2" value="595.2" lower_limit="167.8" upper_limit="1104.8"/>
                    <measurement group_id="O3" value="1055.8" lower_limit="712.1" upper_limit="1778.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Area Under the Curve</title>
        <description>Total AUC with extrapolation using the slope of the β-phase</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>15 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose</title>
            <description>30 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>50 IU/kg rAHF-PFM</description>
          </group>
        </group_list>
        <measure>
          <title>Total Area Under the Curve</title>
          <description>Total AUC with extrapolation using the slope of the β-phase</description>
          <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
          <units>IU*hour/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318.5" lower_limit="131.8" upper_limit="648.8"/>
                    <measurement group_id="O2" value="616.3" lower_limit="194.4" upper_limit="1264.8"/>
                    <measurement group_id="O3" value="1116.0" lower_limit="723.3" upper_limit="2344.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Area Under the Moment Curve</title>
        <description>Total area under the first moment curve (AUMC) estimated by linear trapezoidal methods</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>15 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose</title>
            <description>30 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>50 IU/kg rAHF-PFM</description>
          </group>
        </group_list>
        <measure>
          <title>Total Area Under the Moment Curve</title>
          <description>Total area under the first moment curve (AUMC) estimated by linear trapezoidal methods</description>
          <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
          <units>IU*hour^2/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4760.9" lower_limit="1042.9" upper_limit="16315.9"/>
                    <measurement group_id="O2" value="7115.1" lower_limit="2673.6" upper_limit="28374.2"/>
                    <measurement group_id="O3" value="16464.7" lower_limit="7111.4" upper_limit="77439.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight-adjusted Clearance</title>
        <description>Computed as weight-adjusted dose divided by total AUC</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>15 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose</title>
            <description>30 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>50 IU/kg rAHF-PFM</description>
          </group>
        </group_list>
        <measure>
          <title>Weight-adjusted Clearance</title>
          <description>Computed as weight-adjusted dose divided by total AUC</description>
          <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
          <units>mL/kg*hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.71" lower_limit="2.34" upper_limit="11.38"/>
                    <measurement group_id="O2" value="4.88" lower_limit="2.37" upper_limit="15.43"/>
                    <measurement group_id="O3" value="4.47" lower_limit="2.13" upper_limit="6.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time</title>
        <description>Computed as total AUMC divided by total AUC</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>15 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose</title>
            <description>30 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>50 IU/kg rAHF-PFM</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time</title>
          <description>Computed as total AUMC divided by total AUC</description>
          <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="7.2" upper_limit="25.1"/>
                    <measurement group_id="O2" value="12.8" lower_limit="7.5" upper_limit="24.7"/>
                    <measurement group_id="O3" value="14.7" lower_limit="9.2" upper_limit="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State</title>
        <description>Computed as weight-adjusted CL * Mean Residence Time</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>15 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose</title>
            <description>30 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>50 IU/kg rAHF-PFM</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State</title>
          <description>Computed as weight-adjusted CL * Mean Residence Time</description>
          <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
          <units>dL/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.4" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.4" upper_limit="3.4"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.3" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration</title>
        <description>Maximal factor VIII concentration after infusion</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>15 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose</title>
            <description>30 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>50 IU/kg rAHF-PFM</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration</title>
          <description>Maximal factor VIII concentration after infusion</description>
          <population>Per protocol population: participants who were randomized, received all 3 doses of rAHF-PFM, and had pharmacokinetic assessments.</population>
          <units>IU/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0" lower_limit="13.0" upper_limit="42.0"/>
                    <measurement group_id="O2" value="50.0" lower_limit="14.0" upper_limit="79.0"/>
                    <measurement group_id="O3" value="93.0" lower_limit="65.0" upper_limit="143.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-infusion Von Willebrand Factor Ristocetin Cofactor Activity (VWF:Rco)</title>
        <description>Percentage of normal VWF:Rco activity. Normal is a lab standard consisting of a non-hemophilic population. Relationships between baseline VWF:Rco and pharmacokinetic parameters (initial recovery, total AUC/dose, and half-life) were evaluated statistically.</description>
        <time_frame>At baseline and before each pharmacokinetic evaluation</time_frame>
        <population>Intent to treat: participants who received at least 1 of the 3 infusions of rAHF-PFM and had pharmacokinetic evaluation(s)</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>15 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose</title>
            <description>30 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>50 IU/kg rAHF-PFM</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-infusion Von Willebrand Factor Ristocetin Cofactor Activity (VWF:Rco)</title>
          <description>Percentage of normal VWF:Rco activity. Normal is a lab standard consisting of a non-hemophilic population. Relationships between baseline VWF:Rco and pharmacokinetic parameters (initial recovery, total AUC/dose, and half-life) were evaluated statistically.</description>
          <population>Intent to treat: participants who received at least 1 of the 3 infusions of rAHF-PFM and had pharmacokinetic evaluation(s)</population>
          <units>Percent of normal VWF:Rco activity</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.0" lower_limit="40" upper_limit="152"/>
                    <measurement group_id="O2" value="80.5" lower_limit="49" upper_limit="186"/>
                    <measurement group_id="O3" value="80.5" lower_limit="33" upper_limit="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Regression analysis: Relationship of initial recovery to pre-infusion level of VWF:Rco with dose groups combined.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7048</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Regression analysis: relationship of AUC/Dose to pre-infusion level of VWF:Rco with dose groups combined.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0322</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Regression analysis: relationship of terminal half-life to pre-infusion level of VWF:Rco with dose groups combined.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0056</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-infusion Von Willebrand Factor Antigen (VWF:Ag)</title>
        <description>Percentage of VWF:Ag. Relationships between baseline VWF:Ag and pharmacokinetic parameters (initial recovery, total AUC/dose, and half-life) were evaluated statistically.</description>
        <time_frame>At baseline and before each pharmacokinetic evaluation</time_frame>
        <population>Intent to treat: participants who received at least 1 of the 3 infusions of rAHF-PFM and had pharmacokinetic evaluation(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>15 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose</title>
            <description>30 IU/kg rAHF-PFM</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>50 IU/kg rAHF-PFM</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-infusion Von Willebrand Factor Antigen (VWF:Ag)</title>
          <description>Percentage of VWF:Ag. Relationships between baseline VWF:Ag and pharmacokinetic parameters (initial recovery, total AUC/dose, and half-life) were evaluated statistically.</description>
          <population>Intent to treat: participants who received at least 1 of the 3 infusions of rAHF-PFM and had pharmacokinetic evaluation(s).</population>
          <units>U/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.0" lower_limit="57" upper_limit="307"/>
                    <measurement group_id="O2" value="117.0" lower_limit="63" upper_limit="309"/>
                    <measurement group_id="O3" value="109.5" lower_limit="61" upper_limit="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Regression analysis: relationship of initial recovery to pre-infusion level of VWF:Ag with dose groups combined.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3696</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Regression analysis: relationship of AUC/Dose to pre-infusion level of VWF:Ag with dose groups combined.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Regression analysis: relationship of terminal half-life to pre-infusion level of VWF:Ag with dose groups combined.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons.</p_value_desc>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 months</time_frame>
      <desc>AEs were collected by the investigators at study visits, and may result from laboratory and vital sign assessments collected or measured at the study visits</desc>
      <group_list>
        <group group_id="E1">
          <title>Safety Population (26 Participants)</title>
          <description>Participants who received at least 1 infusion of rAHF-PFM</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Baxter’s agreements with PIs vary per individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 1 year after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥45 days prior to submission or communication. Baxter may request an additional delay of up to 60 days (e.g., to allow for intellectual property protection).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wing-Yen Wong, MD, Global Sr Medical Dir Hemophilia</name_or_title>
      <organization>Baxter Healthcare Corporation</organization>
      <email>wing_yen_wong@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

